Research and Clinical Trials

Title  
University of Virginia UVA-LACC-PD201: A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cervical Cancer
Brief Description  
The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Cervix
Status  
OPEN
Start Date  
04/10/2017
IRB Number  
00019485
Principal Investigator  
Crane, Erin King
Contact Name  
Heather N Neagle

For More Information, Contact  Heather  N, Neagle
Phone:  980-442-2303 Fax:    
Email:  heather.neagle@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close